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The Keap1/Nrf2 pathway is a key mediator of general redox and tissue-specific
homeostasis. It also exerts a dual role in cancer, by preventing cell transformation of
normal cells but promoting aggressiveness, and drug resistance of malignant ones.
Although Nrf2 is well-studied in other tissues, its roles in the thyroid gland are only recently
emerging. This review focuses on the involvement of Keap1/Nrf2 signaling in thyroid
physiology, and pathophysiology in general, and particularly in thyroid cancer. Studies
in mice and cultured follicular cells have shown that, under physiological conditions,
Nrf2 coordinates antioxidant defenses, directly increases thyroglobulin production and
inhibits its iodination. Increased Nrf2 pathway activation has been reported in two
independent families with multinodular goiters due to germline loss-of-function mutations
in KEAP1. Nrf2 pathway activation has also been documented in papillary thyroid
carcinoma (PTC), due to somatic mutations, or epigenetic modifications in KEAP1, or
other pathway components. In PTC, such Nrf2-activating KEAP1 mutations have been
associated with tumor aggressiveness. Furthermore, polymorphisms in the prototypical
Nrf2 target genes NQO1 and NQO2 have been associated with extra-thyroidal extension
and metastasis. More recently, mutations in the Nrf2 pathway have also been found
in Hürthle-cell (oncocytic) thyroid carcinoma. Finally, in in vitro, and in vivo models of
poorly-differentiated, and undifferentiated (anaplastic) thyroid carcinoma, Nrf2 activation
has been associated with resistance to experimental molecularly-targeted therapy. Thus,
Keap1/Nrf2 signaling is involved in both benign and malignant thyroid conditions, where
it might serve as a prognostic marker or therapeutic target.
Keywords: thyroid, Nrf2 (nuclear factor erythroid 2-related factor 2), Keap1 (Kelch-like ECH-associated protein 1),
thyroglobulin, oxidative stress, goiter, antioxidant
INTRODUCTION
Reactive oxygen species (ROS), such as hydrogen peroxide (H2O2), are required for normal thyroid
cell proliferation as well as for synthesis of the main hormones secreted by thyroid follicular
cells, triiodothyronine (T3), and thyroxine (T4) (1–3). However, an unchecked excess of ROS can
cause oxidative stress (OS), a factor involved in the pathogenesis of a broad spectrum of diseases,
including inflammation, and cancer (4). Thus, thyroid follicular cells need to protect themselves
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against OS, and recent research has shown that one such
protective mechanism is the antioxidant response pathway
centered on the nuclear factor erythroid 2-related transcription
factor 2 (Nrf2). Nrf2 is a conserved leucine zipper protein that
plays a central role in tissue proteostasis by upregulating the
transcription of a battery of antioxidant defense genes, and
downregulating the transcription of proinflammatory cytokines
(5–7). In basal conditions, Nrf2 is bound to its cytoplasmic
inhibitory complex formed by Kelch-like ECH-associated protein
1 (Keap1) and Cullin 3 (Cul3), wherein Keap1 targets Nrf2 for
polyubiquitination by Cul3 leading to subsequent degradation
via the proteasome. Under conditions of OS, specific redox-
reactive cysteines of Keap1 become oxidized, thereby abolishing
its ability to target Nrf2 for polyubiquitination, and degradation
(8–10). Nrf2 is thus stabilized and accumulates in the nucleus,
where it binds to DNA sequences called Antioxidant Response
Element (AREs) that are located in the promoters, and enhancers
of its numerous target genes (11). A model illustrating the
pathway, its activation mode, and some of its main target
genes is shown in Figure 1. The major importance of Nrf2
in health preservation has been convincingly demonstrated via
studies in Nrf2 knockout (KO) mice. Tissues of these mice show
decreased expression levels of antioxidant and cytoprotective
genes, and proteins like NAD(P)H quinone oxidoreductase 1
(Nqo1, a prototypical Nrf2 target gene), glutathione peroxidase
2 (Gpx2), and thioredoxin reductase 1 (Txnrd1). Conversely,
oxidative damage to various tissues is increased (12). Nrf2
KO mice are viable, and fertile (13), but they are highly
sensitive to challenges with various factors that trigger OS or
other related cellular stresses; as a result of such exposures,
Nrf2 KO mice develop respective pathologies, and thus serve
as experimental models for the corresponding diseases (12,
14). This multiple-organ protection effect is likely due to the
fact that Nrf2 not only regulates a wide range of ubiquitous
cell-protective genes, but it also regulates the expression of
tissue-specific genes involved in the specialized functional,
and homeostatic mechanisms of each respective tissue (15).
Nrf2 is ubiquitously expressed and it has been well-studied in
several tissues; however, its roles in the thyroid gland are only
recently starting to be addressed, with emerging evidence that
supports indeed the existence of both general antioxidant as
well as thyroid-specific physiological functions (16). This review
summarizes the recent work on Keap1/Nrf2 signaling in thyroid
physiology, and pathophysiology in general and in thyroid cancer
in particular.
PHYSIOLOGY
Recent studies have shown that Nrf2 is a key antioxidant
player in the thyroid gland. In vivo work using mice and rats
demonstrated that Nrf2 promotes the transcription and protein
synthesis of antioxidant and cytoptotective molecules such as
Nqo1, Gpx2 and Txnrd1 in the thyroid gland (16, 17); of
note, the latter two were long known to have roles that are
necessary for the proper functioning of thyroid follicular cells
(18, 19). In vitro studies in thyroid follicular cells indicate that
these regulations take place in a cell-autonomous manner (16).
These effects are present in basal conditions (16), and they
are much more prominent in conditions of iodine overload
(16, 17). Indeed, pharmacological doses of iodine induce the
production of oxidative substances in thyroid follicular cells
(16, 17). Given the fact that iodine is a fundamental component
of thyroid hormones, this potentially reflects an exacerbation
of a physiological phenomenon, whereby a certain oxidative
state is necessary to facilitate normal thyroid hormone synthesis
(2). In wild-type mice, despite an increased oxidative burden
in response to iodine overload, oxidized protein and lipid
levels do not increase (16); this indicates that endogenous
antioxidant defenses are mobilized to prevent OS. Importantly,
this protection is lost in Nrf2 KO mice, whose thyroid tissue
shows increased levels of oxidized proteins, and lipids in
response to pharmacological doses of iodine (16). Indeed, such
exposures induce the transcription of genes encoding antioxidant
and cytoprotective proteins like Nqo1, and Gpx2 (16, 17);
this induction occurs in a Nrf2-dependant manner, because
it is abolished in Nrf2 KO mice (16). Thus, it appears that
Nrf2 plays a fundamental role in the protection of thyroid
follicular cells against the constant oxidative conditions induced
by iodine.
Interestingly, activation of Nrf2 by iodine, with subsequent
upregulation of its target genes, has also been documented in
human skin (20). This suggests that there may exist at least two
mechanisms whereby iodine activates Nrf2: one that is specific to
the thyroid and is related to the physiological oxidation reactions
involving iodine as part of the process of thyroid hormone
synthesis; and another that is either specific to the skin or shared
among tissues.
In addition to its antioxidant defense effects, Nrf2 also plays a
specific role in thyroidal functions. Studies in mice and cultured
follicular cells have shown that Nrf2 has a dramatic impact on
both the basal and the thyroid-stimulating hormone (TSH)-
induced intra-thyroidal abundance of thyroglobulin (Tg) (16),
which is the main protein produced by the gland, and the
precursor molecule of T3 and T4. Nrf2 positively regulates the
transcription of the gene encoding Tg via direct binding to
two AREs in a conserved upstream enhancer (16). In Nrf2 KO
mice, Tg production is effectively reduced; the same is true in
cultured follicular thyroid cells, both in basal conditions, and
in response to TSH stimulation (16). Another striking effect of
Nrf2 is that it decreases Tg iodination, which is an essential step
in thyroid hormone synthesis; in Nrf2 KO mice, the thyroidal
levels of iodinated Tg are thus highly increased, especially in
response to excess iodine (16). The mechanisms involved in this
latter phenomenon warrant further elucidation; one proposed
hypothesis is that Nrf2 activation reduces the levels of oxidative
species, thereby reducing the efficiency of the oxidative reactions
involved in Tg iodination. The various effects of Nrf2 on thyroid
physiology are summarized in Figure 2.
In summary, Nrf2 emerges as an important regulator of
thyroid follicle physiology: it increases the levels of Tg needed
for hormone synthesis, prevents its excessive iodination, and
protects against intrathyroidal oxidative damage, especially
under conditions of iodine overload.
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FIGURE 1 | The Keap1/Nrf2 system. Under basal conditions, Nrf2 is bound to its cytoplasmic inhibitory complex formed by Keap1 and Cul3 that targets Nrf2 for
polyubiquitination and subsequent degradation by the proteasome. When oxidative stress occurs, the interaction between Nrf2 and the inhibitory complex is
abrogated, leading to accumulation of de novo synthesized Nrf2 in the nucleus. Nrf2 then promotes the transcription of antioxidant and cytoprotective genes via
binding to Antioxidant Response Elements (AREs) located in the genes’ regulatory regions. Cul3: Cullin3; Rbx1: RING-box protein 1; E2: ubiquitin-conjugating enzyme
2; Ub: Ubiquitin; Keap1: Kelch-like ECH-associated protein 1; Nrf2: nuclear factor erythroid 2-related transcription factor 2; NQO1: NAD(P)H quinone dehydrogenase
1; GPX2: glutathione peroxidase 2; TXNRD1: thioredoxin reductase 1; GCLC: glutamate-cysteine ligase, catalytic subunit; GCLM: glutamate-cysteine ligase, modifier
subunit; HO-1: heme oxygenase 1.
GOITER
Two independent case reports have described patients with
hereditary multinodular goiters who harbored respective
germline loss-of function mutations of KEAP1, leading to
increased Nrf2 activation (21, 22). The first mutation was
found in a 5-generation Japanese family presenting familial
non-toxic goiter inherited in an autosomal dominant pattern
(21). Genetic analysis revealed a heterozygous mutation in
exon 3 of KEAP1, resulting in a single base-pair (bp) deletion
and frameshift mutation (c.879_880delinsA, p.Asp294Thr,
fs∗23). This mutation affects the IVR (intervening region)
domain of Keap1, which is responsible for its dimerization
and its interaction with Cul3, as shown in Figure 3. In affected
individuals, no Keap1 protein was generated by the mutant
allele in the thyroid, and thus the total wild-type Keap1 protein
levels in the thyroid were decreased. The mRNA levels of the
gene encoding Nrf2 (NFE2L2, for NFE2-like 2) were unchanged,
but the mRNA levels of GSTA4 (Glutathione S-transferase
A4), and GCLC (glutamate cysteine ligase, catalytic subunit)
were increased (21). Since both these genes are known to be
transcriptionally activated by Nrf2 in other tissues (23, 24), the
data indicate that the heterozygous KEAP1 loss-of-function
mutation leads to activation of Nrf2.
The second germlinemutation was described in amiddle-aged
Japanese woman with coexisting non-toxic multinodular goiter
and Graves’ disease, whose family history was also notable for
goiter in her father, and two paternal aunts (22). Genetic analysis
identified a heterozygous single point mutation (c.1448G>A,
p.R483H) in KEAP1, affecting the Keap1 protein’s DC (DGR
and CTR, double-glycine repeat and C-terminal region) domain,
responsible for Nrf2 binding, as shown in Figure 3 (22).
Histological analysis of the patient’s thyroid nodules after total
thyroidectomy showed increased Nrf2 nuclear accumulation,
indicating altered Keap1/Nrf2 interaction (22). Interestingly, this
same mutation had been previously described as a somatic event
in non-small cell lung carcinoma tissue samples, where it was
also accompanied by increasedNrf2 nuclear accumulation and by
increased mRNA levels of NFE2L2, which is itself a target gene of
Nrf2 (25), as well as by increased mRNA levels of the Nrf2 target
genes NQO1, andMRP2 (multidrug resistance protein 2) (26).
These two independent examples (21, 22) show that loss-
of-function mutations in KEAP1 can be a driver event in
some rare forms of hereditary non-toxic multinodular goiter,
and suggest that the genetic activation of Nrf2 is a likely
goitrogenic mechanism in such cases. The relevance of these
observations for the pathogenesis of more common forms of
sporadic nodules, and goiters remains to be addressed. However,
regardless of any broader relevance for the pathogenesis of
goiter, these cases are important because they suggest that there
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FIGURE 2 | Schematic representation of demonstrated and proposed
pleiotropic functions of Nrf2 in follicular thyroid cells under basal conditions
and in response to iodine overload. The solid arrows indicate mechanisms that
have been sufficiently demonstrated experimentally. Nrf2: nuclear factor
erythroid 2-related transcription factor 2; ROS: Reactive Oxygen Species; Tg:
thyroglobulin. The dotted arrows indicate putative mechanisms that require
further investigation. Originally published in Ziros et al. (16); used here with
permission from Mary Ann Liebert Inc.
may be some particularities regarding Keap1/Nrf2 signaling in
the thyroid as compared to other tissues: It can be reasonably
assumed that in the patients harboring germline KEAP1 loss-
of-function mutations, Nrf2 was activated in all tissues. Yet,
only the thyroid showed a prominent clinical phenotype leading
to the diagnosis, and no extra-thyroidal diseases were reported
in the same patients (21, 22). It is thus possible in theory
that KEAP1 haploinsufficiency may lead to more potent Nrf2
activation in the thyroid as compared to other tissues, or that
the thyroid may be more sensitive than other tissues to similar
increases in the activation status of the Nrf2 pathway (or
both). Systematic surveillance, and extended phenotyping of the
affected individuals in these families, as well as of any others
that may be identified in the future, could help address this very
intriguing question.
Another question raised by these observations concerns the
thyroidal safety of compounds that activate Nrf2. One such
compound, dimethyl fumarate (DMF) is already approved for
the treatment of two different diseases (multiple sclerosis and
psoriasis), and several others are being tested in clinical trials
for other indications (27). Such indications include both the
treatment of specific diseases, as well as the prevention of various
pathologies associated with OS and/or environmental exposures
to toxicants or pollutants, the so-called “chemoprevention” of
disease (27). The cases of patients with KEAP1 loss-of-function
mutations described above suggest that the constitutive and life-
long genetic activation of Nrf2 can lead to goiter (21, 22). This
raises the question of whether the pharmacological activation
of Nrf2 in children or adults (potentially lasting from weeks
to decades, depending on the disease and the treatment), may
have similar effects. It therefore appears prudent to monitor
both thyroid function and thyroid volume (at least by palpation)
in patients treated with Nrf2-activating compounds on a
therapeutic or experimental basis. In that sense, consumption
of a broccoli sprout beverage (yielding pharmacologically active
amounts of the Nrf2-activating compound sulforaphane) has
been recently shown to be safe for thyroid hormonal, and
autoimmune status during a 12-week randomized trial (28).
Other Nrf2-activating regimens should also be tested on an
individual basis, to ensure their safety for the thyroid gland.
Priority should be given to antioxidant compounds, known or
suspected to affect thyroid function from in vitro, and preclinical
studies, as summarized in a recent review (29).
THYROID CARCINOMAS
Pathogenesis and Prognosis
Despite the low rate of proliferation of thyroid follicular cells
(30), thyroid tumors (benign or malignant) are quite frequent
in the general population. Indeed, even though human thyroid
cells divide only about five times during adulthood (30), the
spontaneous mutation rate is much higher in the thyroid than
in other tissues (31). This might account, at least in part, for the
relatively high incidence of thyroid malignancies. About 1.3% of
men and women will be diagnosed with thyroid cancer in their
lifetime, and this incidence is growing in the last decades (32).
Regarding the types of mutations found in thyroid carcinomas,
genetic analyses indicate that single-base modifications (but not
strand breaks or abasic sites) are more frequent than in cancers
of other organs (31). Given that OS preferentially induces single-
base mutations (33), these data suggest that mutations found in
thyroid carcinomas are mainly due to OS-related DNA damage.
In that context, the oxidant H2O2, a prerequisite for iodine
oxidation and Tg iodination, could be causally implicated in the
high mutagenesis rate of the thyroid (34), further supporting
the importance of antioxidant mechanisms to ensure redox
homeostasis. Furthermore, cells of established tumors also try
to protect themselves against excessive OS in order to prevent
apoptosis (35). These considerations suggest that the Keap1/Nrf2
pathway, as a key regulator of antioxidant defenses, may play
important roles in the pathophysiology of thyroid carcinomas.
In that sense, it is also noteworthy that Nrf2 has been described
to participate in the regulation of DNA repair signaling after
induction of DNA damage by ionizing radiation to colonic cells
(36). Given that ionizing radiation to the neck before adulthood is
a well-known risk factor for thyroid cancer (37), Nrf2 activation
could potentially be a means of prevention against carcinogenesis
in this case. More generally, based on studies of carcinomas
arising in various other tissues, Nrf2 is known to exert a dual
role in cancer, by preventing cell transformation of normal cells
but promoting aggressiveness, and drug resistance of malignant
ones (38–41). The various studies discussed below demonstrate
that these concepts extend also to thyroid carcinomas, and they
highlight some particularities of the involvement of Keap1/Nrf2
signaling in these specific tumors.
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FIGURE 3 | Schematic structure of the Keap1 protein and mutations involved in thyroid gland disorders. Functional regions are indicated with corresponding amino
acid number. Dotted lines and rectangles represent germline mutations involved in hereditary multinodular goiter. Solid lines and rectangles represent somatic
mutations involved in thyroid cancers. Cul3: Cullin 3; NTR: netrin-like domain; BTB: Broad-Complex, Tramtrack and Bric-a-Brac; IVR: Intervening Region; DRG:
Double-Glycine Repeat; DC: DGR and CTR, double-glycine repeat and C-terminal region; CTR: C-terminal Region; NTR: N-terminal Region; NH2: amino-terminal
end; COOH: carboxy-terminal end.
In papillary thyroid carcinoma (PTC), the most common
thyroidal malignancy, immunohistochemical analysis showed
that the protein levels of Nrf2 andNqo1were higher in carcinoma
tissues compared to benign follicular adenomas and hyperplastic
nodules; both proteins were undetectable in normal thyroid
parenchyma adjacent to the PTC samples (42). The oxidized
lipid 4-hydroxynonenal (4-HNE) was more abundant in PTC
than in adjacent normal tissue, indicating the presence of OS
in the cancer, and suggesting that antioxidant defense in PTC
is somehow impaired, and/or insufficient to prevent oxidative
damage (42). Interestingly, there was no correlation between the
protein levels of Nrf2 and Nqo1 in PTC samples, neither between
the protein levels of Nrf2 and Keap1; these observations argue
against Keap1 downregulation as the principal mechanism of
Nrf2 overexpression in PTC, and further suggest that the Nrf2
pathway is not only activated but also at least partially perturbed
in PTC (42). In the same study, in vitro work with cell lines
representing normal human thyrocytes and PTC cells showed
that Nrf2 pathway activation promoted the viability of the PTC
cell lines but not of normal cells, suggesting that inhibition of
Nrf2 may be a potential therapeutic strategy in PTC (42).
In order to characterize the molecular mechanisms leading
to Nrf2 activation in thyroid carcinoma, mutations in the
Keap1/Nrf2 pathway were sought (42–44). KEAP1, and NFE2L2
somatic mutations have been identified and characterized
in various human cancers, including lung, liver, renal, and
squamous cell cancers, leukemia, and others (40). Sequencing
of PTC samples did not reveal any mutations in NFE2L2
(and particularly in its known mutational hotspot in exon 2
that encodes one of the domains responsible for the binding
to Keap1) (42–44); however, several different mutations were
identified in KEAP1, albeit at a very low overall frequency (43,
44). The different somatic mutations identified in KEAP1 in
thyroid tumors are shown in Figure 3, Table 1. This is consistent
with data showing that, in thyroid tumors overexpressing Nrf2,
NFE2L2 mRNA levels are not increased and may even be
decreased, indicating that increased Nrf2 expression is due to
post-transcriptional alterations rather than direct transcriptional
upregulation (44). In carcinomas harboring a KEAP1 mutation,
immunohistochemical analysis showed increased expression of
Nrf2 in comparison with normal parenchyma, suggesting a
decreased inhibitory effect of Keap1 on Nrf2 (43).
In addition to mutations in the genes encoding the core
components of the pathway (KEAP1 andNFE2L2), modifications
of their promoter sequences and of genes encoding other
regulators of the pathway were also considered (44). Indeed,
alterations of genes encoding the regulators comprising the
Keap1/Cul3/Rbx1 E3-ubiquitin ligase complex that targets Nrf2
for proteasomal degradation, appear to be extremely frequent
in PTC, because more than 80% of samples harbored a DNA
alteration in at least one component of this complex (44). In
contrast with DNAmutations, which were rare, copy number loss
and promoter hypermethylation were often present; for example,
these were the most common alterations affecting RBX1, and
KEAP1, respectively. Hypermethylation in the promoter region
of genes can cause gene silencing and this phenomenon can
contribute to carcinogenesis (48). Silencing of KEAP1 gene
by hypermethylation has been described in several cancers
(49). Specifically, KEAP1 gene hypermethylation is associated
with stabilized Nrf2 and increased expression of Nrf2 target
genes in lung (45), colorectal (50), and prostate cancer (51).
In cancers harboring such epigenetic alterations, prognosis
is generally worse because cancer evolution is often more
rapid (49).
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TABLE 1 | List of KEAP1 mutations involved in benign and malignant thyroid diseases.
Mutation Inheritance Localization Biological effect Associated disease
c.879_880delinsA, p.D294Y, fs*23 Germline IVR domain Increased Nrf2
pathway activity
familial non-toxic multinodular goiter (NTMG) (21)
[also found in somatic form in lung
adenocarcinoma (45)]
c.1448G>A, p.R483H Germline DC domain Nrf2 nuclear accumulation familial NTMG (22)
[also found in somatic form in lung squamous-cell
carcinoma (26)]
c.483G>A, p.M161I Somatic BTB domain Nrf2 protein overexpression PTC, tall-cell variant (43)
c.781C>T, p.R261W Somatic IVR domain Nrf2 protein overexpression PTC, classical variant (43)
c.1136G>A, p.G379D Somatic DC domain (Kelch 2) Reduced Keap1-Nrf2
interaction Nrf2
protein overexpression
PTC, classical variant (43)
[also found in somatic form in gallbladder
adenocarcinoma (46)]
c.1234C>T, p.P412S Somatic DC domain (Kelch 3) Nrf2 protein overexpression
Nrf2 nuclear accumulation
PTC, classical variant (43)
[also found in somatic form in ovarian
carcinoma (47)]
c.1429G>A, p.G477S Somatic DC domain (Kelch 4) Not tested PTC, unspecified variant (44)
c.1735G>A, p.D579N Somatic DC domain (Kelch 6) Nrf2 protein overexpression PTC, follicular variant (43)
c.1777G>A, p.E593K Somatic DC domain (Kelch 6) Nrf2 protein overexpression PTC, classical variant (43)
IVR: Intervening Region; DC: DGR and CTR, double-glycine repeat and C-terminal region; BTB: Broad-Complex, Tramtrack and Bric-a-Brac; Nrf2, nuclear factor erythroid 2-related
transcription factor 2; PTC, papillary thyroid carcinoma.
In PTC samples harboring such genetic alterations, despite
reduced levels ofNFE2L2mRNA, the mRNA levels of Nrf2 target
genes were increased, consistent with Nrf2 pathway activation
(44). Indeed, genes overexpressed in PTC were enriched in
binding sites for the transcription factors c-Jun or Bach1/Bach
2 (44), which are positive and negative regulators, respectively,
of Nrf2 signaling (52–55). Taken together, these data indicate
that the Nrf2 transcriptional program is activated in PTC due
to frequent concerted genetic mechanisms that disrupt multiple
components of the Nrf2 inhibitory complex (44).
Mutations in NFE2L2 itself are very rare in PTC, with only
one copy number gain in a single sample reported to date
(44). Occasional NFE2L2 and KEAP1 mutations were recently
identified as part of whole-exome sequencing analysis of patient
cohorts with Hürthle-cell (oncocytic) thyroid carcinoma (HCC)
(56, 57), a type of differentiated thyroid carcinoma characterized
by cells with abundant but dysfunctional mitochondria.
To further characterize Nrf2 pathway activation in thyroid
carcinoma, some studies focused on specific upstream regulatory
proteins. One such candidate was BRAF, because it is frequently
activated by somatic mutation in PTC, and because it is a
component of the mitogen-activated protein kinase (MAPK)
pathway that is known to activate Nrf2 signaling in various
contexts. Among PTC samples with strong expression of Nrf2,
the BRAF V600E mutation was not more frequent compared
to a general PTC cohort, suggesting that Nrf2 activation is
not exclusively associated with BRAF mutation (42). Another
study focused on neuregulin 1 (NRG1), a member of the
epidermal growth factor-like family, which was found to be
overexpressed in PTC (58, 59). NRG1 positively impacts Nrf2
protein levels in PTC and stimulates the upregulation of its target
genes, including NQO1, GCLC, and GCLM (glutamate cysteine
ligase, modulatory subunit) (58). The latter genes improve
redox balance, as reflected in a higher ratio of reduced to
oxidized glutathione (GSH/GSSG, GSH being the most abundant
intracellular antioxidant), and this additional protection against
ROS confers a survival advantage to the tumor cells (58). Similar
to experimental knock-down of Nrf2 (42), knock-down of NRG1
abolished the survival advantage of PTC cells, suggesting that
NRG1 may be a potential therapeutic target (58).
In PTC, some studies have associated the activation of the
Keap1/Nrf2 pathway with more aggressive disease. In one such
study, patients with the classical variant or tall-cell (more
aggressive) variant of PTC whose tumors harbored somatic
mutations in KEAP1, showed more frequent extra-thyroidal
extension, and lymph node metastases (two thirds of cases),
and distant metastasis (one third of cases) (43). Moreover, these
patients were all classified as being at intermediate or high
risk for recurrence according to the criteria established by the
American Thyroid Association (60). Of note, KEAP1 mutations
were identified in only a small percentage of patients (<5%) (43).
These findings suggest that the identification of somatic KEAP1
mutations in thyroid carcinomas might serve as an additional
prognostic factor. This concept has been previously established
in patients with non-small cell lung carcinoma (a tumor with
a much higher rate of KEAP1 somatic mutations), where the
presence of such mutations is associated with decreased disease-
free survival and decreased overall survival (26).
Papillary thyroid microcarcinoma (PTMC, i.e., PTC of
≤1 cm), is often an indolent disease that does not always warrant
surgery but may be eligible for active surveillance (61). However,
occasional cases of PTMC show more aggressive behavior,
and can even give local or, more rarely, distant metastases. It
would thus be very useful to identify factors that could predict
aggressive behavior in PTMC, as such patients would not be
good candidates for active surveillance. In that sense, germline
genetic polymorphisms in NQO2, a target gene of Nrf2 (62),
were associated with more aggressive behavior of PTMC (63).
Specifically,NQO2 is known to harbor a tri-allelic polymorphism
that consists of a 29 bp insertion (I29), a 29 bp deletion
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(D), and a 16 bp insertion (I16). Patients with PTMC who
were homozygous for the NQO2 I29 allele were more likely to
have lymph node metastasis at diagnosis compared with PTMC
patients bearing the D allele (63). The association betweenNQO2
I29 homozygosity and lymph node metastasis in PTMC was
confirmed in multivariate analysis. Of note, the prevalence of the
different polymorphisms was similar in patients with PTMC, and
patients with benign hyperplastic nodules (63); this indicates that
the polymorphism is not implicated in the initiation of PTMC
but rather in its progression.
The same study (63) also evaluated a polymorphism inNQO1,
the C609T missense variant, called NQO1∗2. Previously, this
polymorphism had been associated with higher cancer risk
and worse prognosis in breast cancer (64–67), as well as with
higher risk for occupational benzene poisoning, which is a risk
factor for leukemia (68). In PTMC, the NQO1∗2 allele was
associated with extra-thyroidal extension, but without statistical
significance in multivariate analysis (63). It thus does not appear
to have the same prognostic value as the NQO2 I29 allele (63).
Regarding Nqo1, in another study there was no correlation
between the protein levels of Nqo1 (or Nrf2) with either PTC
variants associated with more aggressive behavior (tall-cell,
solid/trabecular, diffuse sclerosing, and oncocytic PTC variants)
or with lymph node metastasis (42). Even though Nrf2 protein
levels were increased in KEAP1-mutated tumors (43), current
evidence does not support a prognostic role for Nrf2 or Nqo1
levels per se. In contrast, expression of heme oxygenase-1 (HO-
1), another target gene of Nrf2 (69), was found to correlate with
thyroid cancer aggressiveness (stage and risk of recurrence, plus a
near-significant trend for extra-thyroidal invasion), but not with
tumor size or lymph node metastasis (70). NRG1 overexpression
was described as a positive prognostic factor for lymph node
metastasis in PTC (58).
Treatment
As mentioned above, Nrf2 is generally known to exert a dual role
in cancer: on the one hand, it prevents cell transformation of
normal cells, and on the other hand, it promotes aggressiveness,
and drug resistance of malignant ones (38–41). The latter, so-
called “dark side” of Nrf2 (71), has been well-studied in other
cancer types, where Nrf2 has been shown to promote resistance
against chemotherapy and radiotherapy (40, 41). Although better
described in lung, and liver carcinomas, such drug resistance
mechanisms and their implications have more recently begun
to be characterized in various models of thyroid carcinoma. It
is thus interesting to discuss various pharmaceutical approaches
that directly or indirectly target the Nrf2 pathway as a strategy for
thyroid cancer treatment.
Proteasome inhibitors are targeted anti-cancer agents that are
in clinical use in other types of cancer. They have also been
used experimentally in patients with thyroid carcinomas without
established alternative treatments, such as metastatic thyroid
carcinomas that are radioiodine-refractory (72). Regarding their
mechanisms of action, as elucidated in other cancer types,
inhibition of the proteasome leads to accumulation of misfolded
proteins, inducing endoplasmic reticulum (ER) stress, and
subsequent apoptosis (73). Apoptosis is induced in part via
induction of CCAAT/enhancer-binding protein homologous
protein (CHOP), activation of the apoptosis signal-regulating
kinase 1 (ASK1)/c-Jun N-terminal kinase (JNK) pathway, and
cleavage of ER-resident caspase-12 (74). Because Nrf2 is degraded
in a proteasome-dependent manner, proteasome inhibition also
generally leads to Nrf2 activation. Thus, a series of studies have
evaluated the involvement of Nrf2 in the sensitivity of thyroid
carcinoma cells lines to proteasome inhibitors. Their results and
conclusions are discussed below and summarized in Figure 4.
In vitro experiments in poorly differentiated thyroid
carcinoma (PTDC) and undifferentiated (anaplastic) thyroid
carcinoma (UTC/ATC) showed that the apoptotic response
to proteasome inhibitor treatment can be predicted by the
induction of CHOP. Cell lines that displayed higher CHOP
protein induction were more sensitive to proteasome inhibitor
treatment, while experimental knock-down of CHOP partially
decreased the effects of the proteasome inhibitor (75). The
expression of the gene encoding CHOP is regulated by several
transcription factors, including oxygen-regulated protein 150
(ORP150), an inducible ER chaperone that suppresses CHOP
expression (76); and Activating Transcription Factor 4 (ATF4),
a transcription factor induced in response to proteasome
inhibition that promotes CHOP expression (77). Both of these
transcription factors can be, at least partially, regulated by
Nrf2 (78). Nrf2 increases ORP150 gene transcription both
directly, by binding to the ORP150 gene promoter, as well as
indirectly, by promoting ATF4 recruitment to the ORP150
gene, which also upregulates its expression (78). At the same
time, Nrf2 antagonizes the recruitment of ATF4 on an ARE
in the CHOP promoter, thereby preventing ATF4-mediated
CHOP transcription (77). Overall, Nrf2 decreases CHOP gene
expression, hence exerting an anti-apoptotic effect in response
to proteasome inhibitor treatment, and thereby favoring drug
resistance. Consistent with the aforementioned mechanisms, cell
lines with low sensitivity to proteasome inhibitor treatment show
increased expression levels of Nrf2, and ORP150 proteins (78).
Experimental knock-down of ORP150 increased the sensitivity
of tumor cell lines that were less responsive to proteasome
inhibitor treatment. These lines also expressed higher CHOP
mRNA levels (76). Similarly, experimental knock-down of Nrf2
inhibited the induction of ORP150 mRNA and protein and
significantly decreased the binding of ATF4 to the ORP150
promoter (78). These findings suggest that pharmacological
inhibition of Nrf2 could be a plausible strategy to increase the
sensitivity of PDTC and UTC to proteasome inhibitors.
Generation of ROS is considered to be a crucial early event
(79) during the initiation of apoptosis induced by the proteasome
inhibitor bortezomib in some types of cancer. Indeed, UTC
cell lines that are less sensitive to bortezomib do not show an
early increase in ROS (80). Additionally, those less sensitive
cell lines show higher levels of GSH, which is associated with
higher expression levels and activity of the Nrf2 target gene
GCLC (80). Moreover, Nrf2 is overexpressed in these cell lines,
suggesting that bortezomib resistance can be due to Nrf2-
mediated synthesis of GSH (80). Other research work using UTC
and PDTC models indicates that p38 MAPK, an important anti-
apoptotic factor activated in response to proteasome inhibition,
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FIGURE 4 | Proposed molecular mechanisms involved in resistance of thyroid carcinoma cells to proteasome inhibitors. Green-labeled molecules promote sensitivity
to proteasome inhibitors, orange-labeled molecules promote resistance to proteasome inhibitors. 1. p38 MAPK phosphorylates Nrf2, thus leading to Nrf2 nuclear
accumulation; 2. Keap1 targets Nrf2 for poly-ubiquitination and proteasomal degradation; 3. Valproic acid demethylates the KEAP1 promoter, thus favoring KEAP1
gene transcription; 4. Nrf2 precludes recruitment of ATF4 to the CHOP promoter, thus decreasing CHOP transcription; 5. ATF4 promotes CHOP transcription via
binding to its promoter; 6. Nrf2 promotes ATF4 recruitment on the ORP150 promoter, thus increasing ORP150 transcription; 7. ATF4 promotes ORP150 transcription
via binding to its promoter; 8. Potential competition between ORP150 and CHOP; 9. Nrf2 promotes ORP150 transcription; 10. Nrf2 promotes HO-1 transcription; 11.
Potentially decreased Keap1-mediated Bcl-XL poly-ubiquitination; 12. Nrf2 promotes GCLC transcription; 13. Gclc protein favors GSH synthesis. MAPK:
Mitogen-activated protein kinase; Keap1: Kelch-like ECH-associated protein 1; Nrf2: nuclear factor erythroid 2-related transcription factor 2; CHOP:
CCAAT/enhancer-binding protein homologous protein; ATF4: Activating Transcription Factor 4; ORP150: oxygen-regulated protein 150; HO-1: heme-oxygenase 1;
Bcl-xL: B-cell lymphoma-extra large; GCLC: glutamate-cystein ligase, catalytic subunit; OS: oxidative stress.
phosphorylates Nrf2, and promotes its accumulation in the
nucleus, thereby inducing the transcription of GCLC (81).
Pharmacological inhibition of p38 MAPK suppresses the nuclear
translocation of Nrf2, thereby enhancing bortezomib-induced
apoptosis, especially in bortezomib-resistant cell lines (81). These
data indicate that the mechanisms by which Nrf2 promotes
resistance to proteasome inhibitors in thyroid cancer are not
limited to interactions with regulators of apoptosis (ATF4,
ORP150, and CHOP), but also include the direct modulation of
the cells’ redox status.
Furthermore, overexpression of Nrf2 in PTC cells confers
resistance to TRAIL (TNF-related apoptosis inducing ligand)
(82). TRAIL is a molecule with growing interest in oncology, as
it specifically triggers cell death (83). In TRAIL-resistant PTC,
combination of the histone deacetylase inhibitor valproic acid
with a TRAIL regimen leads to increased sensitivity both in vitro,
and in vivo (orthotopic mouse model of PTC) (82). Interestingly,
in a different epithelial cell model (human lens), valproic acid is
also known to promote demethylation of the KEAP1 promoter,
leading to upregulation of KEAP1 expression, and subsequent
decreased Nrf2 protein abundance (84). Consistent with this, in
TRAIL-resistant PTC, combination therapy with valproic acid
and TRAIL decreases the nuclear levels, and activity of Nrf2,
leading to downregulation of Bcl-xL, an anti-apoptotic molecule
of the Bcl-2 family (85). Experimental knock-down of Nrf2 also
decreases Bcl-xL protein levels, thereby promoting apoptosis
in cancer cells (82). Interestingly, Keap1 has been shown to
negatively regulate the activity of Bcl-xL by targeting it for poly-
ubiquitination (86). These data indicate that Nrf2 promotes
resistance not only to proteasome inhibitors, but also to other
experimental therapies, and it could thus be considered as a
candidate target to increase sensitivity to such treatments when
they are tested in clinic trials. However, although this approach
to treat/prevent PTC appears mechanistically appealing, it may
have unexpected adverse effects. Indeed, human lens epithelial
cells treated with 5-aza-2′deoxycytidine (a compound known
to promote demethylation of CpG islands in the KEAP1
promoter) displayed increased Keap1 protein levels, decreased
Nrf2 stabilization, enhanced ROS, and increased cell death. These
alterations resulted in a diabetic cataract lens phenotype (87),
which is consistent with the fact that demethylation of theKEAP1
promoter is also associated with enhanced age-related cataract in
humans (88).
Finally, inhibitors of HO-1 have been shown to decrease
proliferation, migration, and invasion of follicular thyroid
carcinoma (FTC) and UTC cell lines, and to reduce FTC tumor
growth in a xenograft model (89). This study demonstrates
that desirable effects on thyroid carcinoma might be achieved
not only by targeting Nrf2 directly, but also potentially by
targeting other components of the Keap1/Nrf2 pathway and its
downstream signaling.
CONCLUSION
In summary, Keap1/Nrf2 signaling is involved in both benign
and malignant thyroid conditions, where it might serve as
a prognosis marker, or therapeutic target. Ongoing research,
including cell culture studies with normal and transformed
thyroid follicular cells, thyroidal phenotyping of animal models,
analysis of human thyroid tissue samples, and monitoring of
thyroid function and volume in clinical studies, is expected
to yield a better understanding of the involvement of Nrf2
in thyroid physiology, and pathophysiology. Such work is
Frontiers in Endocrinology | www.frontiersin.org 8 August 2019 | Volume 10 | Article 510
Renaud et al. Keap1/Nrf2 Signaling in the Thyroid Gland
important in order to ensure the thyroidal safety of Nrf2-
activating compounds that are being developed for use in other
indications, and it might also facilitate the development of new
drugs for the prevention and the treatment of both benign
thyroid diseases, and thyroid carcinomas.
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